Laurent Peyrin‐Biroulet

Research interests

Publications

• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00061-2

• Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2212728

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00467-6

• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00466-4

• Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2020.10.065

• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2020.12.031

• Crohn’s disease

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0156-2

• Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.04.002

• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.01.047

• Ulcerative colitis

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0205-x

• Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1905725

• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900750

• Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

  Gastroenterology · 2019 · https://doi.org/10.1053/j.gastro.2019.10.035

• Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses

  Gastroenterology · 2019 · https://doi.org/10.1053/j.gastro.2019.04.016

• Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus

  Alimentary Pharmacology & Therapeutics · 2017 · https://doi.org/10.1111/apt.13948

• Development of an index to define overall disease severity in IBD

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2016-312648

• ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

  Journal of Crohn s and Colitis · 2016 · https://doi.org/10.1093/ecco-jcc/jjw198

• Crohn's disease

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)31711-1

• 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

  Journal of Crohn s and Colitis · 2016 · https://doi.org/10.1093/ecco-jcc/jjw168

• Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.06.001

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

  Journal of Crohn s and Colitis · 2013 · https://doi.org/10.1016/j.crohns.2013.02.020

• Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

  Nature Genetics · 2011 · 10.1038/ng.764

• Development of the Crohnʼs disease digestive damage score, the Lémann score

  Inflammatory Bowel Diseases · 2010 · https://doi.org/10.1002/ibd.21506

• The Natural History of Adult Crohn's Disease in Population-Based Cohorts

  The American Journal of Gastroenterology · 2009 · 10.1038/ajg.2009.579

Current projects

No projects listed.